Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders Cynaptec’s initial development program is focused on the use of its proprietary Conjugated Psilocin™    compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders.

Conjugated Psilocin™    is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.